ANALYSIS OF MUCOSAL RESPONSES Figure 1 presents different components of the immune response potentially present in mucosal effector sites (some of them are potentially present in inductive sites as well, although in different types or stages and proportions), both in the mucosa and in secretions, and Table 3 presents some of the different techniques available to evaluate them. As techniques used to monitor responses in humans and animals do not usually differ except for specific reagents, they are described together in the following paragraphs. | FIG. 1.Cells and soluble factors present within mucosal tissues and secretions. Cellular analyses are performed mostly on material coming from biopsies or surgery, while soluble mediators (antibodies, cytokines, and chemokines) are preferentially measured in (more ...) |
| TABLE 3. Tests and techniques used in mucosal immunity (humoral and cellular)a |
Humoral responses. (i) Qualification and quantification. Once collected, centrifuged, possibly filtrated, and diluted in appropriate buffers, samples are then analyzed by conventional techniques. For instance, all isotypes can be measured in secretions, but the most commonly analyzed is the IgA isotype. In addition, detecting the presence of the secretory component may help to confirm the nature of the IgA detected (monomeric or dimeric), as only the secreted dimeric form (sIgA) bears this peptide. Alternatively or in addition, high-pressure liquid chromatography techniques may allow discrimination between monomeric and polymeric IgA. The need to quantify dilution and contamination can be addressed by different means. First of all, specific activity can be normalized to the total level of the corresponding isotype present in the same sample (65). This allows calculation of specific activities, according to the formula specific activity = specific Ig/total IgG or IgA. It is also important to compare, in the same assay, the values obtained to those of reference standards, usually purified gamma globulins or pooled sera (65). In addition, it was also demonstrated that mucopolysaccharides in mucosal samples did not interfere with antigen-antibody recognition in enzyme-linked immunosorbent assays (ELISAs), by adding and quantifying in a second step known amounts of specific IgG or IgA (65). Another way to measure dilution in samples induced by lavage is to add to the washing buffer a known product such as lithium as an internal reference, as mentioned before (41). Contamination by serum transudation is also a very important point to consider. In the study using the Perfext method (31), the authors addressed this question by comparing the mucosal tissue/serum antibody titer ratios after immunization by different routes with those obtained after passive intravenous immunization using immune serum with a known titer. They observed that local responses exceeded those in serum and could thus not be explained by transudation of serum antibodies. In addition, they observed that only a few percent of the passively administered antibodies were found in the mucosal tissues. However, this may not always be the case, in particular when measuring mucosal responses that are not fully efficient, and it is important, in particular with humans, to quantify the extent of serum transudation in mucosal secretions if possible. This can be done by measuring the amount of human serum albumin (HSA), since this protein originates exclusively in serum, and it was chosen with the assumption that diffusion of serum IgG and IgA through the mucosae was similar to that of HSA (64). Titration of this protein allowed those authors to calculate a relative coefficient of excretion (RCE) according to the formula (Ig in fluid/HSA in fluid)/(Ig in serum/HSA in serum). The RCE can be calculated either for total Ig or for specific Ig. An RCE significantly greater than 1 indicates local production, and RCE values equal to or near 1 suggest transudation from serum. Contamination with blood can also be addressed by measuring hemoglobin with commercial kits (Sigma). This allows the identification (and elimination) of samples presenting too high values of hemoglobin due to mucosal damage (caused, for instance, by the sampling procedure) or for any other reason. Apart from antibodies, any soluble factor can be measured in a secretion, as long as a sensitive enough assay exists. For instance, cytokines have been successfully detected in saliva or cervical washes (7). However, one has to be aware of potential drawbacks when measuring cytokines, due to their high sensitivity to proteolysis or denaturation, in particular in secretions. (ii) Functional assays. Any functional assay using serum can in theory be performed with mucosal secretions, depending of course on the concentration of the active factor. Below are some examples of tests that can be performed with mucosal antibodies. (a) Allergy (antibody arm). Allergic reactions need antibodies and allergens on the one hand and cells on the other. Antibodies (mainly IgE) present at the mucosal level may be used in such in vitro assays, given that effector cells are available and can be sensitized by such antibodies before challenge with allergen. Alternatively, challenge with allergen can also be done in vivo, and subsequent measurement of IgE or cytokine (interleukin-4 and -13) transcripts can be done by RT-PCR, showing their involvement in allergic reactions (6) (see “Measurement of cellular responses” below). (b) In vitro viral neutralization. IgA antibodies have been shown to neutralize flu virus inside epithelial cells (53). In that work, antihemagglutinin (anti-HA) polymeric IgA (representative of dimeric mucosal sIgA), but not anti-HA IgG, delivered to the basolateral surface colocalized with HA within the cell and induced a reduction in viral titers (in supernatants and cell lysates). IgAs were demonstrated to neutralize virus inside the cells and not in the extracellular medium. Intracellular neutralization and inhibition of transcytosis has also been demonstrated more recently in the case of HIV, still using dimeric (anti-HIV) IgA (5). Neutralization occurred intracellularly within the apical recycling endosome, and immune complexes specifically recycled to the mucosal surface. (c) Passive protection. Such polymeric IgAs have also been demonstrated in the case of flu to mediate passive protection against viral challenge upon intravenous administration, while IgGs were unable to do so (66). Specificity of the protection was also confirmed by administration of anti-IgA antibodies, which eliminated protection. (d) Inhibition of in vitro toxicity. IgA antibodies may also be assessed for their ability to prevent tissue damage mediated by bacteria or their toxins. This has been done, for instance, in the case of Clostridium difficile (75), where polymeric IgA was demonstrated to be more efficient than monomeric IgA or IgG of the same specificity in preventing damage induced in cell culture by C. difficile toxin A. Such tests can in theory be carried out with any toxin from a given pathogen if one has a relevant cell culture. The examples presented above (viral neutralization, passive protection, and inhibition of toxicity) refer to studies in which IgA antibodies (monoclonal, monomeric or polymeric) were used versus IgG and considered effectors of mucosal immunity. However, natural secretions were not used as such. When using high doses of antibodies as in these tests, one has to carefully quantify the reagents used, and any extrapolation to the natural situation and physiological concentration at the mucosal level has to be justified and discussed. Measurement of cellular responses. Although the most characteristic and popular mediators of mucosal immunity are secretory IgAs, they are definitely not the only component of the local immune response. Even when sIgA identification and quantification are of importance, one has to consider that production of these antibodies represents only the final step of a complex process. In addition, the quantification of antibodies or other soluble mediators accumulated in secretions such as cytokines presents some limitations: it brings little information on the dynamic aspects of immune responses and, in particular, is unable to yield information concerning the precise anatomical location(s) of antibody or cytokine formation. The analysis of secretions at the cellular level is more informative in this respect. All in all, it is of great interest to study the mechanisms of antigen presentation (for instance, T- and B-cell regulation or activation of nonspecific cells), among other important parameters at mucosal surfaces. Although they are less easy to perform than tests using secretions because of the sampling step, tests measuring cellular immunity are being used more and more by those working in this field. In fact, once the cells are obtained in sufficient number, any test measuring cellular immunity can be performed, and some examples of such techniques applied to mucosal responses are presented below. (i) Qualification and quantification. (a) ELISPOT (antibodies and cytokines). Since its original description (9), the ELISPOT technique has been employed as an alternative to conventional plaque-forming cell assay to enumerate specific as well as total Ig-secreting cells and also to detect a variety of cells (lymphoid or non lymphoid) secreting factors with immunological properties, such as cytokines (54). Antigen (against which antibodies are directed) or capture antibodies (directed against a cytokine, for instance) are adsorbed onto a solid surface, and in a second step the cells to be analyzed for secretion are added to the wells. After a variable time of incubation depending on the experiment, cells are removed by the use of a detergent (Tween, for instance), and subsequent steps are similar to those used in ELISAs, except for the final revelation step. The secreting cells are then visualized as spots that are then counted under a dissecting microscope. The appearance of spots is different from that of the background, and counting them usually does not constitute a difficult step for someone with some experience. However, it is often time-consuming, and some companies now propose the use of devices for automated counting. The method can be employed to detect secreting cells in suspensions prepared from a variety of animal species (for which reagents exist) and from different anatomic compartments. As stated above, the limiting factors are again the source of cells and the recovery yields. When working on animals, collection of different organs may be rather easy after sacrifice, and this usually allows recovery of significant numbers of cells after appropriate digestion. For humans, the source of cells is usually biopsies or samples obtained after surgery, and in the former case the yields are usually low whatever the technique used to obtain the cells, which may constitute some limitation. A considerable number of studies have used this technique to measure in particular IgA secretory cells in nasal tissue, salivary glands, Peyer's patches, lamina propria, lymph nodes, or spleen (2, 18, 32, 54). Similarly, cytokine-secreting cells have been detected in different mucosal inductive and effector sites, in both animals and humans (36, 54, 77). Spontaneous cytokine secretion can be monitored or, alternatively, such secretion may be quantified after specific antigenic stimulation. The ELISPOT technique can be used with different revelation systems in order to visualize different cells secreting, for instance, different isotypes in the same well (10). It can also be combined with specific purification steps (immunobeads) before incubation (44). Apart from mice, this technique has been used with a large variety of animals from mice to monkeys (81, 82) and, of course, with humans, for detection of IgE to gamma interferon (in gastric biopsies, for instance) (20, 28, 36, 51, 71). However, due to the sometimes limited availability of biopsies, some authors have correlated the detection of antibody-secreting cells in the blood circulation with the level of mucosal antibody responses (60). Actually, when stimulated in inductive sites, cells bearing a mucosal addressin will, over a short window of time (usually about 1 week after induction in mucosal sites), transit through the blood circulation, where they can be picked up and quantified (34, 86). This may constitute a convenient alternative to the use of biopsies when schedules of immunization and sampling are well defined and when a correlation between local and peripheral detection within this interval of time has been clearly demonstrated. (b) Intracellular cytokine staining. As it is of interest to phenotype the very cells that produce cytokines, the use of intracellular cytokine staining may also be applied to mucosal cells. Indeed, this has been done with gastric biopsies from infected volunteers (4). (c) RT-PCR (cytokines, chemokines, and other antigens). A very sensitive way to measure protein expression (cytokine expression in particular) is to use RT-PCR. Given the usually small amount of material obtained from mucosal biopsies or secretions, this technique is of particular interest in this context. As stated in the sampling section above, the way samples are collected is critical in order to avoid RNA degradation. RT-PCR cytokine detection has been described in reports of different studies using biopsies as a starting material, including studies performed with animals (for example, using nasal tissue [6, 50]) and humans (for example, Helicobacter pylori in gastric biopsies [88]). In addition, RT-PCR can be used to detect direct expression of antigens from pathogens, such as H. pylori in dental plaques (58). A similar approach is currently being taken in our department with gastric biopsies, addressing in parallel the expression of cytokines and of different H. pylori antigens (B. Rokbi et al., unpublished data). (d) Expansion of T-cell clones from biopsies. Although the amount of lymphocytes in human biopsies is usually small, some T-cell expansion can be carried out and can allow subsequent analysis using conventional T-cell immunology techniques. Actually, techniques used to generate clones from peripheral blood lymphocytes (PBLs) (13) have been applied to biopsies from bronchial and nasal mucosae or from gastric mucosa (12, 14). Once obtained, clones can be characterized, and their antigenic specificity, phenotype, and cytokine profile can be determined by using autologous Epstein-Barr virus-transformed cells as APCs. One drawback of these techniques is the use of clones resulting usually from a nonspecific polyclonal activation, which in most cases constitutes the first step of the cloning procedure. This may preferentially select some more resistant or activatable clones, regardless of their Th profile or antigenic specificity. We are carrying out similar experiments in our laboratory and have observed that the use of human serum and of culture medium specifically designed for human cells dramatically increased the number of clones that we could get from each biopsy (unpublished observations). (e) APCs and nonspecific immunity. Apart from lymphocytes, identification and quantification of APCs is of interest. Among them, dendritic cells (DCs) are of critical importance, and a growing number of papers highlight the facts that mucosal DCs are different from peripheral ones and that their interactions with mucosal T cells have different consequences. In fact, induction of tolerance is one of the hallmark of mucosal inductive sites, and APCs play a major role in this respect, as indicated by, for example, studies carried out on conjunctival mucosa (15) or respiratory tract DCs (67, 76). In addition, characterization of cells such as phagocytes, in particular resident neutrophils or mast cells, is of critical interest in some pathologies and has to be addressed, possibly by histology or fluorescence-activated cell sorting techniques. (f) Immunohistochemistry, flow cytometry analysis, and more. Techniques used to analyze immune responses in tissue sections apply quite well to the analysis of mucosal immunity. Although the ELISPOT technique is often preferred for the detection of antibodies or cytokines, immunohistochemistry can be used to analyze different cell markers, in situ for instance (16, 72, 80). This can be combined with flow cytometry analysis. (ii) Functional assays. As for secretions, in theory any functional assay in cellular immunity may be applied to mucosal cells, as long as these cells are in sufficient number and in appropriate physiological conditions and status. Below are some examples of cellular functional tests carried out with mucosal or any other type of cells obtained from biopsies. (a) CTLs. Pulmonary cells or cells isolated from mediastinal lymph nodes have often been analyzed in cytotoxic-T-lymphocyte (CTL) assays in the flu model (59). As mentioned before, when cells are isolated from lungs, their local status has to be checked. Other sites may constitute sources for cells presenting CTL activity. CD8+ cells have been expanded from intestinal biopsies of HIV-infected volunteers and characterized by their expression of the mucosal integrin CD103/αEβ7 (70). CTL activity has been measured after expansion of these cells, showing that this kind of test can be carried out, even from a limited starting material. (b) DTH. Apart from CTL responses (usually CD8 mediated), one can address the functionality of resident CD4 Th1 cells in tests such as delayed-type hypersensitivity (DTH). This has been done using nasal CD4 cells in mice (79), in which such cells were demonstrated to mediate DTH, and their presence was associated with protection against flu. Nasal tissue is highly vascularized, and once again when carrying out such studies, the mucosal nature of the cells has to be checked and sampling methods have to be carefully chosen. (c) Role of APCs. DCs or other APCs isolated and characterized as mentioned in the preceding section can also evaluated in functional assays (antigen presentation to T cells, for instance; for a review, see reference 76). The role of DCs in pathogen propagation as in the case of HIV has also been addressed at the mucosal level (74). (d) Nonspecific immunity and mast cells. The role of nonspecific cells is often critical at the mucosal level (phagocytes, including neutrophils, or cells such as mast cells in allergic reactions). In this respect, mucosal mast cells (from intestinal biopsies or lung surgery, among other sources) may be sensitized with IgE of known specificity and concentration before challenge with allergen or stimulated directly with other compounds. Release of mediators can then be quantified (29). This constitutes an evaluation of the cellular arm of an allergic reaction, whose humoral arm was already considered in the preceding section. In addition, the direct role of mast cells in protection can also be addressed at the mucosal level (61). (e) Chemotaxis and chemokines. It may be of interest to investigate the presence of chemotactic substances at the mucosal level. These chemokines may be induced by infection and produced by epithelial cells or other subtypes. These substances can be quantified by classical techniques like ELISA and also can be tested in in vitro chemotaxis assays. In such assays, one can monitor the induced migration of different cell types, and mucosal cells have been evaluated in such assays (30), using, for instance, DCs isolated from Peyer's patches. These studies allowed the phenotyping of different subsets of DCs and correlation of their differential migration to their chemokine receptor expression (CCR6 versus CCR7). (f) M-cell differentiation and function. Assessment of the direct functionality and development of natural intraepithelial or M cells is a difficult task (45), and a study allowing in vitro differentiation of Peyer's patch lymphocytes by cocultivation with the Caco-2 cell line has been helpful in this regard (40). Such a method allowed the lymphocyte-induced reorganization of the epithelial monolayer and the assessment of bacterial (Vibrio cholerae) or antigen uptake and transport through neodifferentiated M cells. Such a model would in theory allow the study of antigen uptake and guide investigators in the search for optimal mucosal formulations (drugs or vaccines), as long as a direct link with these in vitro tests can be done with the in vivo situation (33). (g) Passive transfer of protection against mucosal diseases. Passive transfer of protection can be done with antibodies and also with cells. This is usually done with cells of systemic origin due to the usually high number of cells required in such assays. Alternatively, mucosal T-cell expansion may give sufficient material. In any case, systemic cells can be evaluated for protection against mucosal pathogens, as has been done in the H. pylori model, for instance (56). Other responses and events. (i) Qualification and quantification. (a) Quantification of pathogen load and study of microflora. In challenge studies, usually the most sensitive way to assess protection is to quantify the number of viruses, bacteria, fungi, or parasites present in or on mucosal tissues. This requires tissue or secretion sampling, followed by quantification. This has been done in such pathologies as flu (nasal tissue [53, 66]), HIV (different mucosal tissues [74]), H. pylori infection (gastric or oral tissues [21, 25, 58]), or urinary tract infections (46). It should be noted that a large proportion of pathogens present at mucosal surfaces are often entrapped in the mucus or below it and that when only secretions or superficial layers of mucus are sampled, this presents a clear risk of false-negative results (overoptimistic in the case of vaccination). It is generally more sensitive to sample whole tissue biopsies and to homogenize them (without damaging the pathogen) before quantification (25). The microflora can also be qualified and quantified as well, in order to study any change induced by treatment, procedures (such as nasal intubation [87]), or immunization or to link the presence of one or another type of commensal bacteria to different biological activities. IgA protease-producing bacteria in human nasal mucosa were analyzed (41) for the respective roles of Haemophilus influenzae, Streptococcus pneumoniae, and Streptococcus mitis. (b) Histology and analysis of mucosal modifications. Histology can be performed to study any modification or damage induced by immune responses, treatment, and/or mucosal pathogens (1, 48, 80). These techniques are then usually combined with other tests in the same study (e.g., detection of immune responses or bacterial load), in order to establish correlations if possible. Lung damage induced by allergic reactions can be measured in the light of IgE responses, for instance (72). Damage induced by nasal intubation may also be assessed by histology (87), as can changes induced by immunotherapy (8, 19). This type of study should also be done when testing new mucosal adjuvants and formulations, in which adjuvanticity may also be linked to local toxicity (for a review, see reference 68). (c) In vitro mucosa. It may also be of great interest to use in vitro-reconstituted mucosa to have an easy way to monitor any change occurring at mucosal surfaces and to be able to perform kinetic studies on released mediators. For example, work has been done on nasal mucosa (cell lines or excised nasal epithelium; for a review, see reference 55). Nasal chambers of different types allowing study of the influence of other parameters such as humidity and airflow have been designed and optimized (J. Turner and Oya Alpar [Aston University], personal communication). These devices can be linked to confocal microscopy, allowing kinetic studies of antigen uptake. (ii) Functional assays. The presence of bacteria or cells may also be measured by their enzymatic activities (41, 42, 48), but one has to be aware that because the sensitivity of the enzymatic assays is sometimes not high enough, this kind of test may need to be reserved for qualification rather than quantification of pathogens (23, 25). |
REFERENCES 1. Ahlstedt, I., C. Lindholm, H. Lönroth, A. Hamlet, A. M. Svennerholm, and M. Quinding-Järbrink. 1999. Role of local cytokines in increased gastric expression of the secretory component in Helicobacter infection. Infect. Immun. 67:4921-4925. [PubMed]. 2. Asanuma, H., C. Aizawa, T. Kurata, and S. Tamura. 1998. IgA antibody forming cell responses in the NALT of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 16:1257-1263. [PubMed]. 3. Aufricht, C., W. Tenner, H. R. Salzer, A. E. Khoss, E. Wurst, and K. Herkner. 1992. Salivary IgA concentration is influenced by the saliva collection method. Eur. J. Clin. Chem. Clin. Biochem. 30:81-83. [PubMed]. 4. Bamford, K. B., X. Fan, S. E. Crowe, J. F. Leary, W. K. Gourley, G. K. Luthra, E. G. Brooks, D. Y. Graham, V. E. Reyes, and P. B. Ernst. 1998. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a Th1 phenotype. Gastroenterology 114:482-492. [PubMed]. 5. Bomsel, M., M. Heyman, H. Hocini, S. Lagaye, L. Belec, C. Dupont, and C. Desgranges. 1998. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9:277-287. [PubMed]. 6. Cameron, L., Q. Hamid, E. Wright, Y. Nakamura, P. Christodoulopoulos, S. Muro, S. Frenkiel, F. Lavigne, S. Durham, and H. Gould. 2000. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure. J. Allergy Clin. Immunol. 106:46-52. [PubMed]. 7. Cencia Rohan, L., R. P. Edwards, L. A. Kelly, K. A. Colenello, F. P. Bowman, and P. A. Crowley-Nowick. 2000. Optimization of the Weck-Cel collection method for quantitation of cytokines in mucosal secretions. Clin. Diagn. Lab. Immunol. 7:45-48. [PubMed]. 8. Churchill, M., A. Chadburn, R. T. Bilinski, and M. M. Bertagnolli. 2000. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune profile. J. Surg. Res. 89:169-175. [PubMed]. 9. Czerkinsky, C., C. Nilsson, H. Nygren, Ö. Ouchterlony, and A. Tarkowsky. 1983. A solid phase enzyme-linked immunospot (ELISPOT) assay for enumeration of antibody secreting cells. J. Immunol. Methods 65:109-121. [PubMed]. 10. Czerkinsky, C., Z. Moldoveanu, J. Mestecky, L. A. Nilsson, and Ö. Ouchterlony. 1988. A novel two colour ELISPOT assay. J. Immunol. Methods 115:31-37 [PubMed]. 11. Czerkinsky, C., F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren, M. P. Kieny, K. Fujiyashi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J. B. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197-222. [PubMed]. 12. D'Elios, M. M., M. Manghetti, F. Almerigognia, A. Amedei, F. Costa, D. Burroni, C. T. Baldari, S. Romagnani, J. L. Telford, and G. F. Del Prete. 1997. Different cytokine profile and antigen specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur. J. Immunol. 27:1751-1755. [PubMed]. 13. Del Prete, G. F., M. De Carli, C. Mastromauro, R. Biagiotti, D. Macchia, P. Falagiani, M. Ricci, and S. Romagnani. 1991. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (Th1 and Th2) profile of cytokine production. J. Clin. Invest. 88:346-350. [PubMed]. 14. Del Prete, G. F., M. De Carli, M. M. D'Elios, P. Maestrelli, M. Ricci, L. Fabbri, and S. Romagnani. 1993. Allergen exposure induces the activation of allergen specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur. J. Immunol. 23:1445-1449 [PubMed]. 15. Egan, R. M., C. Yorkey, R. Black, W. K. Loh, J. L. Stevens, E. Storozynsky, E. M. Lo, J. G. Frelinger, and J. G. Woodward. 2000. In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. J. Immunol. 164:4543-4550. [PubMed]. 16. Elitsur, Y., S. Jackman, C. Neace, S. Keerthy, X. Liu, J. Dosescu, and J. A. Moshier. 1998. Human vaginal mucosal immune system: characterization and function. Gen. Diagn. Pathol. 143:271-277. [PubMed]. 17. Elson, C. O., W. Ealding, and J. Lefkowitz. 1984. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J. Immunol. Methods 67:101-108. [PubMed]. 18. Erdile, L., and B. Guy. 1997. Osp A lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Vaccine 15:988-996. [PubMed]. 19. Erel, F., M. Karaayvaz, A. Z. Caliskaner, M. Gerek, M. Demiriz, A. Kubar, and N. Ozanguc. 2000. Effects of allergen immunotherapy on the nasal mucosa in patients with allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 10:14-19. [PubMed]. 20. Eriksson, K., M. Quiding-Jarbrink, J Osek, I. Nordstrom, M. Hjulstrom, J. Holmgren, and C. Czerkinsky. 1999. Anatomic segmentation of the intestinal immune response in nonhuman primates: differential distribution of B cells after oral and rectal immunizations to sites defined by their source of vascularization. Infect. Immun. 67:6210-6212. [PubMed]. 21. Ferguson, D. A., Jr., C. Li, N. R. Patel, W. R. Mayberry, D. S. Chi, and E. Thomas. 1993. Isolation of Helicobacter pylori from saliva. J. Clin. Microbiol. 31:2802-2804. [PubMed]. 22. Fergusson, A., K. A. Humphreys, and N. M. Croft. 1995. Results of immunological tests on faecal extracts are likely to be extremely misleading. Clin. Exp. Immunol. 99:70-75. [PubMed]. 23. Ferrero, R. L., J.-M. Thiberge, M. Huerre, and A. Labigne. 1994. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect. Immun. 62:4981-4989. [PubMed]. 24. Grewal, H. M. S., T. H. Karlsen, H. Vetvik, C. Ahren, H. K. Gjessing, H. Sommerfelt, and B. Haneberg. 2000. Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J. Immunol. Methods 339:53-62. 25. Guy, B., C. Hessler, S. Fourage, J. Haensler, E. Vialon-Lafay, B. Rokbi, and M. J. Quentin Millet. 1998. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 16:850-856. [PubMed]. 26. Guy, B., S. Fourage, C. Hessler, V. Sanchez, and M. J. Quentin Millet. 1998. Effect of the site and nature of adjuvant of a parenteral immunization with a flu vaccine on the serum and mucosal immune responses induced by a nasal boost with nonadjuvanted vaccine. Clin. Diagn. Lab. Immunol. 5:732-736. [PubMed]. 27. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J. P. Kraenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method of collection of secretions from local mucosal surfaces. Infect. Immun. 62:15-23. [PubMed]. 28. Hanke, T., T. J. Blanchard, J. Schneider, C. M. Hannan, M. Becker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. McMichael. 1998. Enhancement of MHC class I restricted peptide specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439-445. [PubMed]. 29. Harari, Y., N. W. Weisbrodt, and F. G. Moody. 2000. Ileal mucosal response to bacterial toxin challenge. J. Trauma 49:306-313. [PubMed]. 30. Iwasaki, A., and B. L. Kelsall. 2000. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine. J. Exp. Med. 191:1381-1394. [PubMed]. 31. Johansson, E. L., C. Rask, M. Fredriksson, K. Eriksson, C. Czerkinski, and J. Holmgren. 1998. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with CTB subunit or conjugates. Infect. Immun. 66:514-520. [PubMed]. 32. Jones, P. D., and G. L. Ada. 1986. Influenza virus-specific ASCs in the murine lung during primary influenza virus infection. J. Virol. 60:614-619. [PubMed]. 33. Kaiserlian, D., and N. Etchart. 1999. Entry sites for oral vaccines and drugs: a role for M cells, enterocytes and dendritic cells? Semin. Immunol. 11:217-224. [PubMed]. 34. Kantele, A., J. M. Kantele, E. Savilhati, M. Westerholm, H. Arvilommi, A. Lazarovits, E. C. Butcher, and P. H. Mäkelä. 1997. Oral, but not parenteral typhoid vaccination induces ASCs that all bear homing receptors homing to the gut. J. Immunol. 158:574-579. [PubMed]. 35. Kantele, A., M. Häkkinen, Z. Moldoveanu, A. Lu, E. Savilahti, R. D. Alvarez, S. Michalek, and J. Mestecky. 1998. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect. Immun. 66:5630-5635. [PubMed]. 36. Kartunnen, R., T Kartunnen, H. P. T. Ekre, and T. T. McDonald. 1995. IFNγ and IL-4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36:341-345. [PubMed]. 37. Kato, H., H. Bukawa, E. Hagiwara, K. Q. Xin, K. Hamajima, S. Kawamoto, M. Sugiyama, E. Noda, M. Nishizaki, and K. Okuda. 2000. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine 18:1151-1160. [PubMed]. 38. Kaul, R., F. A. Plummer, J. Kimani, T. Dong, P. Kiama, T. Rostron, E. Njagi, K. S. McDonald, J. J. Bwayo, A. J. McMichael, and S. L. Rowland-Jones. 2000. HIV-1 specific mucosal CD8+ lymphocyte responses in the cervix of Hiv-1-resistant prostitutes in Nairobi. J. Immunol. 164:1602-1611. [PubMed]. 39. Kawabata, S., Y. Terao, T. Fujiwara, I. Nakagawa, and S. Hamada. 1999. Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A (IgA) and IgG antibodies and serum Ig in mice. Infect. Immun. 67:5863-5868. [PubMed]. 40. Kerneis, S., A. Bogdanova, J. P. Kraehenbuhl, and E. Pringault. 1997. Conversion by Peyer's patch lymphocytes of human enterocyte into M cells that transport bacteria. Science 277:949-952. [PubMed]. 41. Kirkeby, L., T. T. Rasmussen, J. Reinhold, and M. Killian. 2000. Immunoglobulins in nasal secretions of healthy humans: structural integrity of sIgA1 and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria. Clin. Diagn. Lab. Immunol. 7:31-39. [PubMed]. 42. Klimek, L., and G. Rasp. 1999. Norm values for eosinophil cationic protein in nasal secretions: influence of specimen collection. Clin. Exp. Allergy 29:367-374. [PubMed]. 43. Kozlowski, P. A., S. Cu-Uvin, M. R. Neutra, and T. P. Flanigan. 1997. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65:1387-1394. [PubMed]. 44. Lakew, M., I. Nordstöm, C. Czerkinsky, and M. Quiding-Järbrink. 1997. Combined immunomagnetic cell sorting and ELISPOT assay for the phenotypic characterization of specific antibody-forming cells. J. Immunol. Methods 203:193-198 [PubMed]. 45. Laky, K., L. Lefrançois, E. G. Lingenheld, H. Ishikawa, J. M. Lewis, S. Olson, K. Suzuki, R. E. Tigelaar, and L. Puddington. 2000. Enterocyte expression of IL-7 induces development of gammadelta T cells and Peyer's patches. J. Exp. Med. 191:1569-1580. [PubMed]. 46. Langermann, S., R. Mollby, J. E. Burlein, S. R. Palaszinski, C. G. Auguste, A DeFusco, R. Strouse, M. A. Schenerman, S. J. Hultgren, J. S. Pinkner, J Winberg, L. Guldevall, M. Soderhall, K. Ishikawa, S. Normark, and S. Koenig. 2000. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic E. Coli. J. Infect. Dis. 181:774-778. [PubMed]. 47. Laufer, D. S., W. Hurni, B. Watson, W. Miller, J. Ryan, D. Nalin, and L. Brown. 1995. Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine. Clin. Infect. Dis. 20:868-875. [PubMed]. 48. Lee, C. K., R. Weltzin, W. D. Thomas, H. Kleanthous, T. Ermak, G. Soman, J. E. Hill, S. Ackerman, and T. P. Monath. 1995. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 172:161-167. [PubMed]. 49. Losonsky, G. A., G. T. Fantry, M. Reymann, and Y. Lim. 1999. Validation of a gastrointestinal explant system for measurement of mucosal antibody production. Clin. Diagn. Lab. Immunol. 6:803-807. [PubMed]. 50. Matsuo, K., T. Iwasaki, H. Asanuma, T. Yoshikawa, Z. Chen, H. Tsujimoto, T. Kurat, and S. Tamura. 2000. Cytokine mRNAs in the nasal-associated lymphoid tissue during influenza virus infection and nasal vaccination. Vaccine 18:1344-1350. [PubMed]. 51. Mattson, A., M. Quiding-Jarbrink, H. Lonroth, A. Hamlet, I. Ahlstedt, and A. M. Svennerholm. 1998. Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect. Immun. 66:2705-2712. [PubMed]. 52. Mayer, L. 2000. Mucosal immunity and gastrointestinal antigen processing. J. Pediatr. Gastroenterol. Nutr. 30:(Suppl) :S4-S12 [PubMed]. 53. Mazanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular neutralization of influenza virus by IgA anti-hemagglutinin monoclonal antibodies. J. Virol. 69:1339-1343. [PubMed]. 54. Mega, J., J. R. McGhee, and H. Kiyono. 1992. Cytokine and Ig-producing cells in mucosal effector tissues. Analysis of IL-5 and IFNγ producing T cells, T cell receptor expression, and IgA plasma cells from mouse salivary glands associated tissues. J. Immunol. 148:2030-2038. [PubMed]. 55. Merkle, H. P., G. Ditzinger, S. R. Lang, H. Peter, and M. C. Schmidt. 1998. In vitro models to study nasal mucosal permeability and metabolism. Adv. Drug Deliv. Rev. 29:51-79. [PubMed]. 56. Mohammadi, M., S. Czinn, R. Redline, and J. Nedrud. 1996. Helicobacter specific cell-mediated immunity responses display a predominant Th1 phenotype and promote a delayed type hypersensitivity response in the stomachs of mice. J. Immunol. 156:4729-4738. [PubMed]. 57. Nederfors, T., and C. Dahlof. 1993. A modified device for collection and flow-rate measurement of submandibular-sublingual saliva. Scand. J. Dent. Res. 101:210-214. [PubMed]. 58. Nguyen, A. M., L Engstrand, R. M. Genta, D. Y. Graham, and F. A. K. El-Zaatari. 1993. Detection of Helicobacter pylori in dental plaque by RT-PCR. J. Clin. Microbiol. 31:783-787. [PubMed]. 59. Nguyen, H. H., F. W. van Ginkel, H. L. Vu, M. J. Novak, J. R. McGhee, and J. Mestecky. 2000. Gamma interferon is not required for mucosal cytotoxic T lymphocyte responses or heterosubtypic immunity to influenza virus infection in mice. J. Virol. 74:5495-5501. [PubMed]. 60. Nieminen, T., H. Käythy, A. Virolainen, and J. Eskola. 1998. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 16:313-319. [PubMed]. 61. Onah, D. N., F. Uchiyama, Y. Nagakui, M. Ono, T. Takai, and Y. Nawa. 2000. Mucosal defense against gastrointestinal nematodes: responses of mucosal mast cells and mouse mast cell protease 1 during primary Strongyloides venezuelensis infection in FcRgamma-knockout mice. Infect. Immun. 68:4968-4971. [PubMed]. 62. Quesnel, A., S. Cu-Uvin, D. Murphy, R. L. Ashley, T. Flanigan, and M. Neutra. 1997. Comparative analysis of methods for collection and measurement of immunoglobulins in cervical and vaginal secretions of women. J. Immunol. Methods 202:153-161. [PubMed]. 63. Raux, M., L. Finkielsztein, D. Salmon-Ceron, H. Bouchez, J. L. Excler, E. Dulioust, J. M. Grouin, D. Sicard, and C. Blondeau. 2000. IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res. Hum. Retroviruses 16:583-594. [PubMed]. 64. Raux, M., L. Finkielsztein, D. Salmon-Ceron, H. Bouchez, J. L. Excler, E. Dulioust, J. M. Grouin, D. Sicard, and C. Blondeau. 1999. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV1-infected subjects. AIDS Res. Hum. Retroviruses 15:1365-1376. [PubMed]. 65. Raux, M., L. Finkielsztein, D. Salmon-Ceron, H. Bouchez, J. L. Excler, E. Dulioust, J. M. Grouin, D. Sicard, and C. Blondeau. 1999. Development and standardization of methods to evaluate the antibody response to an HIV1 candidate vaccine in secretions and sera of seronegative recipients. J. Immunol. Methods 222:111-124. [PubMed]. 66. Renegar, K. B., and P. A. Small, Jr. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1972-1978. [PubMed]. 67. Reynolds, H. Y. 2000. Advances in understanding pulmonary host defense mechanisms of dendritic cell function and immunomodulation. Curr. Opin. Pulm. Med. 6:209-216. [PubMed]. 68. Ronco, J., and B. Guy. 2000. Adjuvants for mucosal vaccines, p. 28-69. In R. Fuller and G. Perdigon (ed.), Probiotics 3: immunomodulation by the gut microflora and probiotics. Kluwer Academic Publishers, Dordrecht, The Netherlands. 69. Rudin, A., E. L. Johansson, C. Bergquist, and J. Holmgren. 1998. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect. Immun. 66:3390-3396. [PubMed]. 70. Shacklett, B. L., T. J. Beadle, P. A. Pacheco, J. H. Grendell, P. A. Haslett, A. King, G. S. Ogg, P. M. Basuk, and D. F. Nixon. 2000. Characterization of HIV-1 specific cytotoxic T lymphocytes expressing the mucosal lymphocyte integrin CD 103 in rectal and duodenal lymphoid tissue of HIV-1-infected subjects. Virology 270:317-327. [PubMed]. 71. Shinomyia, N., M. Kumai, D. G. Marsh, and S. K. Huang. 1993. Detection of specific IgE secreting cells with an enzyme-linked immunospot assay. J. Allergy Clin. Immunol. 92:479-485 [PubMed]. 72. Simecka, J. W., R. J. Jackson, H. Kiyono, and J. McGhee. 2000. Mucosally induced IgE-associated inflammation in the respiratory tract. Infect. Immun. 68:672-679. [PubMed]. 73. Sklavinskis, L. S., C. Barnfield, L. Gao, and S. Parker. 1999. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J. Immunol. 162:254-262. [PubMed]. 74. Stahl-Hennig, C., R..M. Steinman, K. Tenner-Racz, M. Pope, N. Stolte, K. Matz Rensing, G. Grobschupff, B. Raschdorff, G. Hunsmann, and P. Racz. 1999. Rapid infection of oral mucosal associated lymphoid tissue with simian immunodeficiency virus. Science 285:1261-1265. [PubMed]. 75. Stubbe, H., J. Berdoz, J. P. Kraehenbuhl, and B. Corthesy. 2000. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing C. difficile toxin A damaging T84 monolayers. J. Immunol. 164:1952-1960. [PubMed]. 76. Stumbles, P. A. 1999. Regulation of T helper cell differentiation by respiratory tract dendritic cells. Immunol. Cell Biol. 77:428-433. [PubMed]. 77. Taguchi, T., J. R. McGhee, R. L. Coffman, K. W. Beagley, J. H. Eldridge, K. Takatsu, and, H. Kiyono. 1990. Analysis of Th1 and Th2 cells in murine gut associated tissues; frequencies of CD4+ and CD8+ cells that secrete IFNg and IL5. J. Immunol. 145:68-76 [PubMed]. 78. Takayanagi, A., T. Nomura, S. Yamanaka, and Y. Takaesu. 1995. A modified device for long term sampling of parotid saliva in various experimental conditions. Bull. Tokyo Dent. Coll. 36:69-73. [PubMed]. 79. Tamura, S., K. Miyata, K. Matsuo, H. Asanuma, H. Takahashi, K. Nakajima, Y. Suzuki, C. Aizawa, and T. Kurata. 1996. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156:3892-3900. [PubMed]. 80. Trajman, A., T. T. McDonald, and C. C. Elia. 1997. Intestinal immune cells in Strongyloides stercoralis infection. J. Clin. Pathol. 50:991-996. [PubMed]. 81. van Besouw, N. M., P. H. van der Meide, and N. P. M. Bakker. 1994. The mitogen-induced generation of interferon gamma producing cells in cultures of rhesus monkey PBMC is age dependant. J. Med. Primatol. 23:42-47. [PubMed]. 82. VanCott, J. L., T. A. Brim, R. A. Simkins, and L. J. Saif. 1993. Isotype specific antibody secreting cells to transmissible gastroenteritis virus and porcine respiratory coronavirus in gut and bronchus associated lymphoid tissues of suckling pigs. J. Immunol. 150:3990-3997. [PubMed]. 83. van Ginkel, F. W., H. H. Nguyen, and J. R. McGhee. 2000. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg. Infect. Dis. 6:123-132. [PubMed]. 84. Veerman, E. C., P. A. van den Keybus, A. Vissink, and A. V. Nieuw Amerongen. 1996. Human glandular salivas: their separate collection and analysis. Eur. J. Oral Sci. 104:346-352. [PubMed]. 85. Vetvik, H., H. M. S. Grewal, I. L. Haugen, C. Ahren, and B. Haneberg. 1998. Mucosal antibodies can be measured in air dried samples of saliva and feces. J. Immunol. Methods 215:163-169. [PubMed]. 86. Viret, J. F., D. Favre, B. Wegmuller, C. Herzog, J. U. Que, S. J. Cryz, and A. B. Lang. 1999. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 67:3680-3685. [PubMed]. 87. Westrgren, V., N. Otori, and P. Stierna. 1999. Experimental nasal intubation: a study of changes in nasoantral mucosa and bacterial flora. Laryngoscope 109:1068-1073. [PubMed]. 88. Yamaoka, Y., M. Kita, T. Kodama, N. Sawai, and J. Imanishi. 1996. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 110:1744-1752. [PubMed]. |